RecruitingNot ApplicableNCT06724185

Effects of LP28 on Immunity Enhancement in the Elderly


Sponsor

Synbio Tech Inc.

Enrollment

100 participants

Start Date

Jul 9, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Due to the increasing attention on aging-related health issues, this study focuses on the elderly population as participants. The aim is to investigate whether supplementation with Lactobacillus plantarum LP28 can effectively enhance immunity, reduce the frequency and severity of common cold infections, and ultimately promote overall health in the elderly.


Eligibility

Min Age: 50 YearsMax Age: 75 Years

Inclusion Criteria1

  • Those who had symptoms of common cold or tonsillitis at least twice in the past year.

Exclusion Criteria5

  • People who have liver, kidney, immune, or neoplastic diseases diagnosed by doctor.
  • People with mental illnesses such as schizophrenia or depression.
  • People who have allergic rhinitis.
  • People who have a current condition of drug or alcohol dependence.
  • Any person is deemed inappropriate by the researcher for the clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTLP28 capsule

LP28 capsule : 5.0×10\^9 CFU/capsule

DIETARY_SUPPLEMENTPlacebo Capsule

Maltodextrin


Locations(2)

National Chung Hsing University

Taichung, Taiwan

Taichung Veterans General Hospital

Taichung, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06724185


Related Trials